Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials
December 12, 2025
Source: drugdu
29
On December 8, Zhaohui Bio-B (02627.HK) announced that the company recently initiated Phase III clinical trials for its lyophilized human rabies vaccine (human diploid cell). The development of this vaccine aims to target three immunization schedules. A new drug clinical trial license was approved by the National Medical Products Administration of the People's Republic of China (NMPA) in November 2022, followed by the approval of supplementary clinical trial applications for the Zagreb (four-dose) and simplified four-dose regimens in April 2023. The company completed the Phase I clinical trial of this investigational vaccine in October 2024.
Rabies is a serious viral disease caused by the rabies virus, and appropriate vaccination can effectively prevent it. Rabies vaccines developed using human diploid cells are recommended by the WHO as the "gold standard" due to their favorable safety characteristics. Although the company demonstrated good safety in the Phase I clinical trials, the announcement also reminded shareholders and potential investors to exercise caution when buying or selling the company's securities.
https://finance.eastmoney.com/a/202512083585378151.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
- Another “disaster” for pre-antibody technology December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
